SOLIRIS (eculizumab): The first treatment specifically approved for PNH

OneSource Program

OneSource ProgramSOLIRIS is the first and only medication that is FDA approved specifically to treat PNH

PNH is a disabling, life-threatening disease with a wide range of signs and symptoms. Every patient's situation is unique, and you may need help with answers to important questions, such as

  • How do you get started?
     
  • Will insurance pay?
     
  • What if you don't have adequate insurance or no insurance at all?
     
  • What happens when you are traveling for business or pleasure?
     
  • How is your insurance affected by relocation, marriage or retirement?

OneSource ProgramThe manufacturer of SOLIRIS® (eculizumab) is dedicated to ensuring that every patient who can benefit from SOLIRIS treatment will have access to SOLIRIS. The SOLIRIS OneSource™ team of registered nurses will work with you, your doctor and your health insurance provider to help with answers to questions about your coverage. OneSource can also help you with information about alternative resources if your insurance is not adequate.

 

In addition to OneSource, become part of the SOLIRIS PNH community. Sign up here.

Additionally, OneSource can help coordinate ongoing treatment by

  • Providing information on the availability and accessibility of SOLIRIS during travel or interruption of the normal treatment schedule
     
  • Helping with information about SOLIRIS treatment during life changes — college, marriage, relocation, retirement

Next: Learn more about the OneSource Program

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS. Revaccinate according to current medical guidelines for vaccine use.

Patients should be monitored closely for early signs of meningococcal infections and evaluated immediately if infection is suspected, and treated with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.